Quest Diagnostics Inc 8-K, filed Mar 16, 2020
Quest Diagnostics Inc (DGX)
8-K
2020-03-16
For: 2020-03-12
View Original
Added on
April 12, 2026
About this 8-K
Quest Diagnostics Inc filed this 8-K on March 16, 2020, reporting on events of March 12, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): March 12, 2020
(Exact Name of Registrant as Specified in Its Charter)
(State or other jurisdiction of incorporation)
(Commission File Number) | (I.R.S. Employer Identification No.) | |||
(Address of principal executive offices) | (Zip Code) | |||
(Registrant's telephone number, including area code) | ||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) On March 12, 2020, the Board of Directors (the "Board") of Quest Diagnostics Incorporated (the "Company") increased its size from 9 to 10 directors. After considering the recommendation of the Board's Governance Committee, the Board elected Wright L. Lassiter, III, President and Chief Executive Officer of Henry Ford Health System, to fill the resulting vacancy, effective immediately.
The Board determined that Mr. Lassiter is an independent director pursuant to the New York Stock Exchange listing standards and the Company’s independence guidelines, as set forth in its corporate governance principles.
The Board appointed Mr. Lassiter to serve on the Board’s Quality, Safety and Compliance Committee.
Mr. Lassiter will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices described in the Company’s proxy statement for its annual meeting of stockholders, filed April 3, 2019. As part of that compensation, Mr. Lassiter received a one-time grant of restricted share units valued at $31,920 upon becoming a member of the Company’s Board.
A copy of the Company’s press release announcing the election is attached hereto as exhibit 99.1 and is hereby incorporated by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
104 The cover page from this current report on Form 8-K, formatted in Inline XBRL.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
March 16, 2020
QUEST DIAGNOSTICS INCORPORATED
By: /s/ William J. O’Shaughnessy, Jr.
William J. O’Shaughnessy, Jr.
Deputy General Counsel and Secretary
Quest Diagnostics Elects Wright Lassiter III to Board of Directors
SECAUCUS, N.J., March 12, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Mr. Wright L. Lassiter III to serve as a director. Including Mr. Lassiter, the company's Board has 10 members.
Mr. Lassiter is the President and CEO of Henry Ford Health System, overseeing a $7.5 billion system comprised of six hospitals, a health plan and a wide range of ambulatory, retail and related health services consisting of more than 250 locations and 32,000 employees. Immediately prior to joining Henry Ford, Mr. Lassiter was CEO of Alameda Health System in Oakland, Calif.
"As a health care leader with over three decades experience in large, complex academic health systems, Wright's insights will be invaluable as we look to make an even bigger impact in the evolving health care landscape," said Steve Rusckowski, Chairman, CEO and President. "We are pleased to welcome him to our Board."
Daniel C. Stanzione, Ph.D., Lead Independent Director, added: "Wright is an innovator, a collaborator and a leader. We are fortunate that he has joined our Board and we look forward to working with him."
Mr. Lassiter currently serves as the Board Vice Chair for the Federal Reserve Bank of Chicago; he also chairs its Governance and Nominating Committee and serves on the Audit Committee. In the non-profit sector, he serves on the boards of LeMoyne College, the Detroit Chamber of Commerce, the Detroit Children's Fund and the Detroit Regional Partnership.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com
CONTACT: For further information: Dennis Moynihan, Quest Diagnostics (Media): 973-520-2800, Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900